Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06795815 | The Implementation of the Go Wish Game to Promote Advance Care Planning in Onco- Hematologic Disease(OHGW-ACP) | recruiting | N/A | 75 | Azienda USL Reggio Emilia - IRCCSOTHER_GOV | 1 | May 7, 2026 | clinicaltrials |
| NCT06926751 | Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors | recruiting | Phase 2 | 132 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 |
| May 7, 2026 |
| clinicaltrials |
| NCT06949943 | Pre-Operative Guided Meditation to Reduce Pre-Operative Anxiety in Patients Undergoing Cancer-Directed Surgery | recruiting | N/A | 300 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT07043894 | Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients | recruiting | Phase 2 | 50 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT03560882 | A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies | active not recruiting | Phase 1 | 50 | Joaquina BarandaOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04439123 | Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y) | active not recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | May 6, 2026 | clinicaltrials |
| NCT04439175 | Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I) | active not recruiting | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | May 6, 2026 | clinicaltrials |
| NCT04745910 | Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome | completed | Phase 4 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT05206942 | Serial Ultrasound of Solid Tumor Lesions to Detect Early Response to Cancer Immunotherapy | suspended | N/A | 30 | Stanford UniversityOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT05642611 | Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy(ICE COMPRESS) | recruiting | Phase 3 | 777 | SWOG Cancer Research NetworkNETWORK | 1 | May 6, 2026 | clinicaltrials |
| NCT05985161 | A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors | recruiting | Phase 2 | 45 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06819735 | Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors(DOMISOL) | recruiting | Phase 1 / Phase 2 | 125 | Domain Therapeutics Australia Pty LtdINDUSTRY | 3 | May 6, 2026 | clinicaltrials |
| NCT07159828 | A Study to Assess AXN-2510 Treatment in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 | 3 | Axion Bio, IncINDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT03217747 | Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies | active not recruiting | Phase 1 / Phase 2 | 173 | M.D. Anderson Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT04871542 | Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors | recruiting | — | 2,062 | SWOG Cancer Research NetworkNETWORK | 5 | May 5, 2026 | clinicaltrials |
| NCT05490771 | Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F) | active not recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | May 5, 2026 | clinicaltrials |
| NCT05711667 | A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients | recruiting | Phase 3 | 105 | Children's Oncology GroupNETWORK | 1 | May 5, 2026 | clinicaltrials |
| NCT06214143 | A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 68 | Shanghai Pharmaceuticals Holding Co., LtdINDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT07566247 | A Phase I Clinical Study of AK150 in Advanced Malignant Solid Tumor | not yet recruiting | Phase 1 | 96 | AkesoINDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT01375114 | The Effects of Ginseng on Cancer-Related Fatigue | active not recruiting | Phase 1 / Phase 2 | 165 | M.D. Anderson Cancer CenterOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT03797326 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | completed | Phase 2 | 611 | Merck Sharp & Dohme LLCINDUSTRY | 17 | May 4, 2026 | clinicaltrials |
| NCT04457778 | First in Human Study of M6223 | completed | Phase 1 | 58 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 2 | May 4, 2026 | clinicaltrials |
| NCT04511039 | Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer | recruiting | Phase 1 | 45 | Roswell Park Cancer InstituteOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT04678427 | Exercise Program (TEAM Me) for the Improvement of Movement and Mobility in Pediatric and Adolescent and Young Adult Patients With Cancer Undergoing a Blood Stem Cell Transplant | recruiting | N/A | 60 | M.D. Anderson Cancer CenterOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05055011 | Parental Attitudes and Beliefs Regarding Risks Associated With Opioid Use in Children With Cancer | active not recruiting | — | 110 | M.D. Anderson Cancer CenterOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05645523 | Indocyanine Green (ICG) Guided Sentinel Lymph Node Mapping for Pediatric Visceral Solid Tumors | recruiting | Early Phase 1 | 25 | St. Jude Children's Research HospitalOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05824663 | A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of HBM1020 in Subjects With Advanced Solid Tumors | completed | Phase 1 | 17 | Harbour BioMed US, Inc.INDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT05865990 | HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease(TUXEDO-3) | completed | Phase 2 | 63 | MedSIROTHER | 2 | May 4, 2026 | clinicaltrials |
| NCT05933265 | Study of LP-184 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 64 | Lantern Pharma Inc.INDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT06132503 | Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors | recruiting | Phase 1 | 110 | Lantern Pharma Inc.INDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT06416007 | Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors | recruiting | Phase 2 | 37 | University of CincinnatiOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT00900497 | A Study Using White Blood Cells From Healthy Donors To Treat Solid Cancers | enrolling by invitation | Phase 1 / Phase 2 | 29 | Dipnarine MaharajOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT04118114 | Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors | completed | Phase 2 | 14 | National Cancer Centre, SingaporeOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT06349837 | Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors | recruiting | Phase 1 | 24 | Sichuan UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07298772 | A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 198 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | May 1, 2026 | clinicaltrials |
| NCT07300943 | Study in Advanced Solid Tumor Patients | recruiting | Phase 1 / Phase 2 | 306 | Callio TherapeuticsINDUSTRY | 2 | May 1, 2026 | clinicaltrials |
| NCT07561437 | NK521 in the Treatment of Malignant Ascites Associated With Advanced Solid Tumors | recruiting | Early Phase 1 | 18 | Base Therapeutics (Shanghai) Co., Ltd.INDUSTRY | 1 | May 1, 2026 | clinicaltrials |
| NCT07561554 | Phase I Study of HSK42360-Na in Solid Tumors With BRAF V600 Mutation | recruiting | Phase 1 | 159 | Haisco Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 1, 2026 | clinicaltrials |
| NCT07562347 | Clinical Experience and Real-world Safety and Effectiveness of Envafolimab: Patient Access Program(ENCOMPASS STUD) | not yet recruiting | — | 120 | IR INNOVATE RESEARCH PRIVATE LIMITEDINDUSTRY | 0 | May 1, 2026 | clinicaltrials |
| NCT01625234 | Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 131 | Xcovery Holdings, Inc.INDUSTRY | 1 | Apr 30, 2026 | clinicaltrials |
| NCT02993146 | Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases | active not recruiting | Phase 1 | 11 | National Cancer Institute (NCI)NIH | 1 | Apr 30, 2026 | clinicaltrials |
| NCT04902040 | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies | terminated | Phase 1 / Phase 2 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT05300048 | Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations | terminated | Phase 1 | 34 | Faeth TherapeuticsINDUSTRY | 1 | Apr 30, 2026 | clinicaltrials |
| NCT05359445 | IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor | active not recruiting | Phase 1 | 95 | Immatics Biotechnologies GmbHINDUSTRY | 1 | Apr 30, 2026 | clinicaltrials |
| NCT05378425 | A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab | active not recruiting | Phase 1 | 90 | Nectin Therapeutics LtdINDUSTRY | 3 | Apr 30, 2026 | clinicaltrials |
| NCT07419581 | A Study of Freeze-Dried Miracle Fruit (MiraBurst) on Participants Receiving Cancer Treatment | not yet recruiting | N/A | 45 | Case Comprehensive Cancer CenterOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07558200 | Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors | not yet recruiting | Phase 1 | 138 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | Apr 30, 2026 | clinicaltrials |
| NCT03218826 | PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 | 23 | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2026 | clinicaltrials |
| NCT03537690 | FID-007 in Treating Participants With Advanced Solid Tumors | active not recruiting | Phase 1 | 50 | University of Southern CaliforniaOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06094426 | Autologous Tumor Infiltrating Lymphocyte Injection for the Treatment of Advanced Solid Tumors | terminated | Early Phase 1 | 2 | Grit BiotechnologyINDUSTRY | 1 | Apr 29, 2026 | clinicaltrials |
Data updated 24 days agoSource updated May 7, 2026source: clinicaltrials